Stock·NASDAQ·Healthcare
REGENXBIO Inc (RGNX)
- Market cap
- $457.14M
- Dividend yield
- 0.00%
- Street target
- $20.00median of 12 analysts
- 52-week range
- $5.46 $16.19
The short version
Where RGNX stands today, in four lines, and what CleaRank Financial AI makes of it.
RGNX at a glance
REGENXBIO Inc (RGNX): Sell, 36/100 on CleaRank's AI score.
- Trend Down: the price is below both its 50- and 200-day moving averages ($8.76 and $9.54).
- Earnings RGNX beat estimates in 3 of its last 7 quarters, yet fell the next day after 1 of those beats.
- Insiders Insiders sold $1.5M and bought $949K over the last 18 months.
Figures as of October 17, 2026.
CleaRank Financial AI
REGENXBIO Inc (RGNX) carries a CleaRank rating of Sell and a model score of 36/100.
The analysts' outlook is the factor that lifts the score most, with 10 of 12 analysts rating the stock a buy and a median target 188.8% above the price. The trend is the heaviest drag: the price sits 27.45% below its 200-day average and 20.97% below its 50-day average, and the 50-day average is 8.20% below the 200-day. The 50-day average is $8.76 and the 200-day is $9.54. Across the past year the price has dropped 43.88%.
Only on CleaRank
Figures we compute ourselves from RGNX's own price, earnings and insider-filing history. Tap one to see it in context.
Price and trading
The chart, today's range and how far the price has moved over each period.
Trend checks
0/4Price above its 50-day average ›
The price of $6.93 is 21.0% below the 50-day simple moving average of $8.76.Price above its 200-day average ›
The price is 27.4% below the 200-day simple moving average of $9.54.50-day average above the 200-day ›
The 50-day average ($8.76) is 8.2% below the 200-day average ($9.54), the arrangement of a falling longer-term trend.In the upper half of its 52-week range ›
The price sits at 14% of its 52-week range, between $5.46 and $16.19.
RGNX share price
Pick a period: each tab shows how far RGNX has moved over it, to the last close.
Today's trading
Where RGNX sits inside today's range and its 52-week range.
Fundamentals
Valuation against the sector, and the revenue and earnings behind it.
Valuation and quality checks
1/3P/S below the sector median ›
The price-to-sales ratio of 2.71 is 20.3% below the sector median of 3.4.Profitable over the last 12 months ›
Net income over the last 12 months was $-196.4M on revenue of $174.5M, a net margin of -112.6%.Beat estimates in most recent reports ›
RGNX beat the EPS estimate in 3 of its last 7 reports.
Key statistics
The headline figures for RGNX.
As of October 17, 2026, RGNX trades at $6.93, with a market value of $457.14M and no P/E ratio (its trailing earnings are negative).
What the numbers say
CleaRank Financial AI's reading of RGNX's valuation, growth and risks.
REGENXBIO Inc (RGNX) has no meaningful P/E, because the company lost money over the last 12 months. Measured against sales, the P/S of 2.71 is 20.3% below the sector median of 3.4. For scale, the company's market value stands at $457.1M.
RGNX is losing money. Its net margin is -112.58% and its operating margin is 27.09%, while return on equity of -137.63% sits below the sector median of 7.3%. Revenue grew 405.70% in the latest year, which is 397.6 percentage points faster than the sector median of 8.1%. Debt-to-equity stands at 3.49.
REGENXBIO Inc (RGNX) beat expectations in its August 6, 2026 report by 490.91%, with EPS of $0.43 against the -$0.11 analysts had forecast. The share price nonetheless dropped 4.96% in the first session after the report.
RGNX beat the EPS estimate in 3 of its last 7 reports, though the stock still fell in the first session after 1 of those 3 beats. The May 14, 2026 report stands out among the earlier ones: a miss of 21.99%, after which the stock fell 8.41%. Analysts' average EPS estimate for this fiscal year is -$3.49, and -$2.98 for next year.
RGNX's daily returns have a 30-day standard deviation of 3.59%. While the price stays under both moving averages, the downtrend itself is a risk. The price is 57.23% below its 52-week high of $16.19. Over the last 18 months insiders sold $1.5M of stock and bought $949K; since sales can be planned in advance or made to cover tax on vesting shares, they carry less weight than purchases.
RGNX against the Healthcare sector
How RGNX compares with the median Healthcare stock CleaRank tracks.
Price to sales vs sector: On price-to-sales, the yardstick used here in place of P/E, RGNX trades at 2.71x, -20% versus the sector average of 3.40x.
Return vs XLV: Since May 6, 2025, RGNX has lost 12.6% against a gain of 31.6% for XLV.
Performance against XLV
RGNX and the Healthcare sector fund over the same days.
Revenue and earnings
How much RGNX sells, and how much of it becomes profit.
Revenue growth: Revenue grew 104.5% in FY2025 to $170M, from $83.3M a year earlier.
Profit margin: The net margin was -113.8% in FY2025, up from -272.5% the year before.
Loss-making: RGNX lost $194M in FY2025.
Earnings reality check
Did RGNX beat what analysts expected, and how did the stock react?
Earnings record: RGNX beat the analyst estimate in 3 of the last 7 quarters.
Market reaction: The stock fell in the first session after 1 of those 3 beats, so a beat has not been enough on its own.
| Report | Estimate | Actual | Surprise | First session | 5 sessions |
|---|---|---|---|---|---|
| Aug 6, 2026after close | -$0.11 | $0.43 | +490.91% | -4.96% | -5.50% |
| May 14, 2026after close | -$1.41 | -$1.72 | -21.99% | -8.41% | +8.09% |
| Nov 6, 2025after close | -$1.30 | -$1.20 | +7.69% | +0.36% | +4.21% |
| Aug 7, 2025after close | -$1.05 | -$1.38 | -31.43% | -0.63% | +14.68% |
| May 12, 2025after close | $0.49 | $0.12 | -75.51% | +2.63% | +22.84% |
| Mar 13, 2025after close | -$1.08 | -$1.01 | +6.48% | +2.60% | +27.63% |
| Nov 6, 2024after close | -$1.10 | -$1.17 | -6.36% | +18.66% | +13.15% |
As of October 17, 2026, RGNX has beaten the analyst EPS estimate in 3 of its last 7 reported quarters and fell in the first trading session after 1 of those beats; its latest report, on August 6, 2026, came in 490.91% above the estimate and the stock moved -4.96% in the first session.
The first session is the first full trading day on the news: the report day itself for a report before the open, the next day for one after the close. Surprise is actual EPS against the consensus estimate.
AI analysis and technicals
CleaRank's score and reasoning, the indicators behind it, and what the price moves with.
Momentum checks
1/3RSI not overbought or oversold ›
The 14-day RSI is 37.0, showing bearish momentum without being oversold.RSI above 50 ›
An RSI of 37.0 is below the 50 midpoint, so sellers have had the upper hand over the last 14 days.MACD line above zero ›
The MACD line is negative, so the 12-day average is below the 26-day average.
CleaRank AI analysis of RGNX
The score, the reasoning behind it, and what could move the price next.
REGENXBIO Inc (RGNX) shows a downtrend: the price of $6.93 sits 20.97% below its 50-day average of $8.76 and 27.45% below the 200-day average of $9.54, so both averages lie overhead. The price is at 14% of its 52-week range, 26.95% above the 52-week low of $5.46. The two averages agree on direction, with the 50-day 8.20% below the 200-day.
On momentum, the 14-day RSI reads 37.0, in the bearish zone, above the oversold line, with the MACD line negative. Every period on the chart shows a loss, with the price down 29.98% over the past three months, 27.03% over the past six months and 43.88% over the past year.
Earnings beat ›
The August 6, 2026 report beat the EPS estimate by 490.91%, and the share price fell 4.96% in the first session after it.
Source: Earnings report, August 6, 2026New analyst coverage ›
Mizuho started coverage at Outperform on October 5, 2026.
Source: Analyst action, Mizuho, October 5, 2026
Analyst downgrade ›
Barclays downgraded it to Equal-Weight from Overweight on August 7, 2026.
Source: Analyst action, Barclays, August 7, 2026
- The two closest levels matter most: the 20-day EMA at $7.64 above the price, and the 52-week low at $5.46 below it.
- The 14-day RSI is 37.0, in the bearish zone, and the MACD line is negative. Readings above 70 or below 30 point to stretched momentum.
- The share price dropped 4.96% in the first session after the August 6, 2026 report, even though RGNX beat estimates in 3 of the last 7 reports.
RGNX stays in a downtrend while it trades below both its 50-day average of $8.76 and its 200-day average of $9.54. A close back above the 50-day would be the first sign of a repair. Overhead, the 20-day EMA at $7.64 is the first hurdle.
The next level below the price is the 52-week low at $5.46. With the RSI in the bearish zone, momentum argues against a quick recovery.
Technical indicators
Momentum and trend for RGNX, from its daily closes.
As of October 17, 2026, with RGNX at $6.93, its 14-day RSI is 37.0 (showing bearish momentum without being oversold), its 50-day simple moving average is $8.76 and its 200-day is $9.54.
Calculated by CleaRank on daily closes as of October 17, 2026: Wilder's 14-day RSI, 50- and 200-day simple moving averages, MACD line (12, 26).
What RGNX moves with
Correlation of daily returns over one year: +1 moves in step, 0 has no link, -1 moves the opposite way.
As of October 17, 2026, RGNX's 1-year correlation of daily returns is +0.32 with S&P 500 (SPY), +0.32 with Nasdaq 100 (QQQ), +0.11 with Bitcoin (BTC) and +0.08 with gold (XAU).
What Wall Street expects
The analysts' target range and how their ratings split.
Analysts checks
2/3Most analysts rate it a buy ›
10 of 12 analysts rate it a buy or strong buy, 2 a hold and 0 a sell.Median target above the price ›
The median 12-month target of $20.00 is 188.8% above the price.More buy ratings than three months ago ›
10 of 12 rate it a buy now, against 10 of 11 three months ago.
RGNX Wall Street View
12-month price targets
The price, $6.93, sits below every analyst's target.
Ratings
Recent rating actions
| Date | Firm | Action | Rating |
|---|---|---|---|
| Oct 5, 2026 | Mizuho | Initiates | Outperform |
| Aug 25, 2026 | HC Wainwright & Co. | Maintains | Buy |
| Aug 25, 2026 | Baird | Maintains | Outperform |
| Aug 10, 2026 | HC Wainwright & Co. | Maintains | Buy |
| Aug 7, 2026 | Barclays | Downgrade | Equal-Weight |
| Jun 24, 2026 | HC Wainwright & Co. | Reiterates | Buy |
As of October 17, 2026, 12 Wall Street analysts cover RGNX: 10 rate it a buy or strong buy, 2 a hold and 0 a sell or strong sell. Their 12-month price targets range from $10.00 to $50.00, with a median of $20.00, 188.8% above the price of $6.93.
Source: TwelveData analyst consensus. Targets and ratings belong to the analysts, not to CleaRank.
A trade plan, if you want one
Entry, stop and target levels from the moving averages and recent volatility. Educational, not advice.
RGNX trade plan
Entry, stop and target levels, sized to your account. Change the bias or the risk and every level updates.
Short entry pick an entry style
Risk management
Profit targets (Based on Conservative Entry)
RGNX moves about 3.6% a day on average, so a stop can fill well past its level. Educational levels, not financial advice; the full disclaimer is at the foot of the page.
Risk profile
How much RGNX tends to move, against the market and on its own.
The long record
RGNX's worst falls and recoveries, what $10,000 became, and which months have been kind to it.
Track record checks
0/4Average daily move under 2% ›
The price has moved 3.59% on an average day (30-day standard deviation of daily returns).Recovered from its worst fall ›
The worst fall was 93.5%, from July 2018 to April 2025; the price is still 91.5% below that peak.Most 1-year holds ended higher ›
35% of 1-year holding periods in the last 10 years ended with a gain.Beat the S&P 500 since the chart begins ›
$10,000 invested in October 2016 is now worth $4,355.35, against $42,055 in the S&P 500 (SPY).
RGNX Drawdowns & Recovery
As of October 17, 2026, RGNX's worst peak-to-trough fall over the last 10 years with dividends reinvested was -93.5% (July 2018 to April 2025); it is still 91.5% below that peak, and 35% of 1-year holding periods ended with a gain.
From weekly closing values with dividends reinvested. A drawdown is the fall from the highest value reached so far to a later low.
Growth of $10,000
What $10,000 put into RGNX in October 2016 is worth now, against the same amount in the S&P 500.
Against the market: RGNX trailed the S&P 500 over this period: $4,355.35 against $42,055.
A $10,000 investment in RGNX in October 2016 would be worth about $4,355 today with dividends reinvested, compared with about $42,055 for the same investment in the S&P 500 benchmark (also with dividends reinvested).
Seasonal patterns
Which calendar months have been kind to RGNX, and which have not.
Strongest month, June: an average of +14.22%, up in 7 of 10 years.
Weakest month, May: an average of -5.43%, up in 3 of 10 years.
This month, October: has averaged -2.64%, up in 4 of 9 years. Past seasonality does not repeat on schedule.
Over the last 10 years, RGNX's strongest calendar month has been June (average +14.22%, up in 7 of 10 years) and its weakest May (average -5.43%, up in 3 of 10 years).
Average return for each calendar month over the last 10 years, from weekly closing prices with dividends included.
Long-term scenarios
Thousands of simulated paths from the price history. A range of outcomes, not a forecast.
Monte Carlo projection
Thousands of simulated paths for $10,000 in RGNX, from its own past volatility. The shaded area holds 80% of them.
CleaRank's 10-year Monte Carlo simulation projects that a $10,000 investment in RGNX today could grow to about $8,522 by 2036 in the base case, with a 90th-percentile outcome near $64,650 and a 10th-percentile outcome around $1,123. Projections are statistical simulations, not guarantees.
RGNX Stock Price Prediction: 2030
The same simulation in share prices, year by year.
CleaRank's simulation projects a price near $6.50 for RGNX by 2030 in the base case, from $6.93 today (0.9x over 4 years). The 10th-percentile path ends near $1.80. These are outcomes of a Monte Carlo simulation run on RGNX's historical return distribution, not price targets, and they assume no dividends are reinvested.
| Year | 10th percentile | Base case | 90th percentile | range base today |
|---|---|---|---|---|
| 2027 | $3.59 | $6.82 | $12.94 | |
| 2028 | $2.71 | $6.71 | $16.60 | |
| 2029 | $2.18 | $6.60 | $20.03 | |
| 2030 | $1.80 | $6.50 | $23.40 | |
| 2031 | $1.53 | $6.39 | $26.79 |
Method: a lognormal simulation of RGNX's own volatility and capped historical trend, re-run daily; base case is the median path, the outer columns the 10th and 90th percentiles.
Insider trading
What the people running the company have bought and sold.
RGNX insider trading
Shares the company's directors and officers bought and sold, from their own filings.
Month by month
Open-market purchases above the line, sales below.
Insider buying: Insiders bought $949K on the open market and sold $1.5M.
As of October 17, 2026, RGNX insiders reported 8 open-market sales worth $1.5M and 1 open-market purchase worth $949K over the last 18 months; grants and option exercises are not counted.
| Date | Insider | Type | Shares | Value |
|---|---|---|---|---|
| Aug 27, 2026 | Gregory Austin Ciongoli
Director
|
Buy | 102.6K | $949.4K |
| Aug 25, 2026 | Gregory Austin Ciongoli
Director
|
Grant | 15.4K | - |
| Jul 2, 2026 | Stephen J Pakola
Officer
|
Sell | 2.2K | $29.5K |
| Jul 2, 2026 | Stephen J Pakola
Officer
|
Option | 2.2K | $17.0K |
| Jul 1, 2026 | Stephen J Pakola
Officer
|
Sell | 56.3K | $688.8K |
| Jul 1, 2026 | Stephen J Pakola
Officer
|
Option | 36.7K | $288.7K |
| Jun 30, 2026 | Curran M Simpson
Chief Executive Officer
|
Grant | 2.4K | $28.5K |
| May 29, 2026 | Jean M.d., Ph.d. Bennett
Director
|
Grant | 9.8K | - |
| May 29, 2026 | Allan Mark Fox
Director
|
Grant | 9.8K | - |
| May 29, 2026 | Alexandra Ph.d. Glucksmann
Director
|
Grant | 9.8K | - |
| May 29, 2026 | Argeris N Karabelas
Director
|
Grant | 9.8K | - |
| May 29, 2026 | George V Migausky
Director
|
Grant | 9.8K | - |
| May 29, 2026 | Kenneth Thomas Mills
Director
|
Grant | 9.8K | - |
| May 29, 2026 | David Carter Stump
Director
|
Grant | 9.8K | - |
| May 29, 2026 | Daniel Tasse
Director
|
Grant | 9.8K | - |
| May 29, 2026 | Jennifer L Zachary
Director
|
Grant | 9.8K | - |
| May 11, 2026 | Stephen J Pakola
Officer
|
Sell | 15.3K | $168.7K |
| Mar 10, 2026 | Stephen J Pakola
Officer
|
Sell | 5.1K | $53.0K |
| Jan 27, 2026 | Kenneth Thomas Mills
Director
|
Option | 225.0K | $2.9M |
| Jan 6, 2026 | Mitchell Chan
Chief Financial Officer
|
Grant | 73.7K | - |
| Jan 6, 2026 | Patrick J. Christmas II
Officer
|
Grant | 73.7K | - |
| Jan 6, 2026 | Craig Malzahn
Chief Technology Officer
|
Grant | 65.8K | - |
| Jan 6, 2026 | Stephen J Pakola
Officer
|
Grant | 65.8K | - |
| Jan 6, 2026 | Curran M Simpson
Chief Executive Officer
|
Grant | 144.9K | - |
| Oct 9, 2025 | Curran M Simpson
Chief Executive Officer
|
Sell | 20.8K | $262.6K |
| Sep 29, 2025 | Curran M Simpson
Chief Executive Officer
|
Sell | 7.6K | $76.5K |
| Sep 10, 2025 | Curran M Simpson
Chief Executive Officer
|
Sell | 7.7K | $77.5K |
| May 30, 2025 | Jean M.d., Ph.d. Bennett
Director
|
Grant | 7.8K | - |
| May 30, 2025 | Allan Mark Fox
Director
|
Grant | 7.8K | - |
| May 30, 2025 | Alexandra Ph.d. Glucksmann
Director
|
Grant | 7.8K | - |
| May 30, 2025 | Argeris N Karabelas
Director
|
Grant | 7.8K | - |
| May 30, 2025 | George V Migausky
Director
|
Grant | 7.8K | - |
| May 30, 2025 | Kenneth Thomas Mills
Director
|
Grant | 7.8K | - |
| May 30, 2025 | David Carter Stump
Director
|
Grant | 7.8K | - |
| May 30, 2025 | Daniel Tasse
Director
|
Grant | 7.8K | - |
| May 30, 2025 | Jennifer L Zachary
Director
|
Grant | 7.8K | - |
| May 12, 2025 | Kenneth Thomas Mills
Director
|
Sell | 20.6K | $163.0K |
| May 12, 2025 | Kenneth Thomas Mills
Director
|
Option | 20.6K | $77.5K |
Source: TwelveData, from SEC Form 4 filings
Questions people ask
Answered from the figures on this page, as of October 17, 2026.